NCI
The biomarker analysis found patients with certain mutations in the PI3K/AKT/mTOR pathway and MAPK pathway may be resistant to Truqap.
NCI Awards up to $150M Under Genomic Characterization Center Contract
The contractors are Sampled, the University of Southern California, UNC Chapel Hill, the New York Genome Center, Washington University in St. Louis, and SeqMatic.
The researchers found biomarkers of macrophage activity and immune activity were associated with resistance and response to Opdivo plus Cabometyx.
NIH Funding Cuts Threaten Research, Clinical Trials, Precision Oncology Progress, Leaders Say
Premium
Researchers warn NIH divestment from research could hinder progress at a pivotal moment for advances in precision cancer medicine.
Biden Cancer Moonshot Announces New Initiatives to Improve Diagnosis, Precision Treatments
The program announced a series of new public and private initiatives and projects designed to support its stated goal of halving the cancer death rate over the next 25 years.
May 21, 2024
Mar 14, 2024
Jul 10, 2023
Jun 1, 2023